Scarica l'app Stockscreener
5.25
1.13%
-0.06
Dopo l'orario di chiusura:
5.49
0.24
+4.57%
Candel Therapeutics Inc Borsa (CADL) Ultime notizie
Candel Therapeutics Announces Publication of Phase 1b - GlobeNewswire
Candel Therapeutics announces publication of Phase 1b trial data on CAN-2409 - TipRanks
Breakthrough: New Brain Cancer Therapy Doubles Survival Time in Key Patient Group - Stock Titan
Candel Therapeutics reveals new data showing better outcomes for glioma patients using CAN-2409 - Proactive financial news
Candel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMI - Proactive financial news
Candel Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:CADL - Benzinga
Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients - Benzinga
Candel Therapeutics Shares Are Down Today: What's Going On? - Benzinga
Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC - Proactive financial news
Candel Therapeutics Clinical Trial for CAN-2409 Demonstrates Promising Survival Extensions for NSCLC Patients Who Failed Previous Therapies - citybiz
Candel Therapeutics Reports Positive Phase 2a Trial Results - TipRanks
Trading (CADL) With Integrated Risk Controls - news.stocktradersdaily.com
Candel Therapeutics Reports Final Phase 2a Survival Data for Lung Cancer Treatment - MarketScreener
Candel Therapeutics Reports Both Prolonged Median Overall Survival And Long Tail Of Survival In Phase 2A Clinical Trial Of CAN-2409 In Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive To Immune Checkpoint Inhibitor (ICI) Treat - MarketScreener
Candel Therapeutics reports positive survival data for CAN-2409 in advanced lung cancer trial - Proactive Investors UK
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatm - GlobeNewswire
Breakthrough: Cancer Drug CAN-2409 Achieves 24.5-Month Survival in Advanced Lung Cancer Patients - Stock Titan
Small cap wrap: Nano One Materials, EnWave, Summit Therapeutics... - Proactive financial news
Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now - Zacks Investment Research
CADLCandel Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Candel therapeutics CEO sells $229,624 in stock By Investing.com - Investing.com Canada
Candel therapeutics chief scientific officer sells $281,672 in stock By Investing.com - Investing.com South Africa
Candel Therapeutics’ chief medical officer sells $396,995 in stock By Investing.com - Investing.com Canada
Candel therapeutics CEO sells $229,624 in stock - Investing.com India
Candel Therapeutics Executives Sell Shares Under Trading Plans - TradingView
Candel Therapeutics’ chief medical officer sells $396,995 in stock - Investing.com
Small cap wrap: Santacruz Silver, GoviEx Uranium, Candel Therapeutics... - Proactive Investors
Candel Therapeutics Partners With IDEA Pharma To Advance CAN-2409 Cancer Immunotherapy - Nasdaq
Candel Therapeutics partners with IDEA Pharma on commercialization of CAN-2409 - Proactive Investors
Candel Therapeutics Partners With IDEA Pharma for CAN-2409 Commercialization -March 20, 2025 at 08:29 am EDT - MarketScreener
Candel Therapeutics and IDEA Pharma Announce Strategic - GlobeNewswire
Breakthrough Prostate Cancer Drug Shows 30% Better Results as Candel Secures Key Partnership - Stock Titan
Candel therapeutics CFO Charles Schoch sells $44,169 in stock - Investing.com India
Candel therapeutics CFO Charles Schoch sells $44,169 in stock By Investing.com - Investing.com South Africa
Candel therapeutics CTO sells $275,947 worth of common stock By Investing.com - Investing.com South Africa
Candel therapeutics CTO sells $275,947 worth of common stock - Investing.com
Small cap wrap: Fineqia, Candel Therapeutics, Ocean Power Technologies, Protalix Biotherapeutics... - Proactive Investors UK
Candel Therapeutics appoints cancer immunology expert to research advisory board - Proactive financial news
Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board - The Manila Times
Candel Therapeutics Appoints Renowned Pancreatic Cancer - GlobeNewswire
Top Pancreatic Cancer Expert Joins Candel Therapeutics Following Promising Trial Results - StockTitan
H.C. Wainwright maintains Buy on Candel Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains Buy on Candel Therapeutics stock - Investing.com India
When (CADL) Moves Investors should Listen - Stock Traders Daily
Candel Therapeutics Reports Positive Clinical Trial Results - TipRanks
Candel Therapeutics eyes CAN-2409 BLA filing, advances cancer pipeline - Proactive financial news
Candel Therapeutics, Inc. SEC 10-K Report - TradingView
Candel Therapeutics Reports Positive Data from Multiple Clinical Trials and Outlines Plans for CAN-2409 and CAN-3110 - Nasdaq
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
1.23%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):